Quidelortho (QDEL) Return on Equity ROE from the second quarter 2026 to second quarter 2025 and annually, average high and low, overall ranking from Jun 28 2026 to Jun 29 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Quidelortho Corp  (NASDAQ: QDEL)

Quidelortho's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Quidelortho in the second quarter 2026?
Quidelortho Corp had a negative return on equity (ROE) of -55.3%, due to the net loss of $-1 billion, during the twelve months ending in the second quarter 2026.

Within the In Vitro & In Vivo Diagnostic Substances industry 5 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 3157 to 3258.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 28 2026)
II. Quarter		 (Mar 29 2026)
I. Quarter		 (Dec 28 2025)
IV. Quarter		 (Sep 28 2025)
III. Quarter		 (Jun 29 2025)
II. Quarter
Y / Y Equity Change -36.45 % -38.23 % -35.65 % -36.1 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -1,048 -1,211 -1,132 -1,180 -466
Return On Equity (TTM) -55.3 % -56.31 % -46.45 % -43.64 % -15.6 %
QDEL's Total Ranking # 3258 # 3157 # 1947 # 2890 # 0
Equity (TTM) in Millions 1,775 1,851 1,921 2,036 2,793
Seq. Equity Change -4.13 % -3.6 % -5.69 % -27.08 % -6.82 %
Seq. Net Income Change - - - - -

Back to QDEL Management Effectiveness >> QDEL's 5 Years Annual ROE >> Compare QDEL ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 6
Sector # 423
Overall # 3258

Return On Equity Statistics
High Average Low
95.36 %
4.39 %
-64.87 %
(Dec 31 2020)   (Dec 29 2024)





QDEL Annual Return On Equity (Dec 28 2025)
2025		 (Dec 29 2024)
2024		 (Dec 31 2023)
2023		 (Jan 01 2023)
2022		 (Dec 31 2021)
2021
Total Equity in Millions 1,921 2,985 5,006 4,935 1,929
Y / Y Equity Change -35.65 % -40.38 % 1.44 % 155.76 % 44.77 %
Net Income in Millions -1,132 -2,052 -10 549 704
Y / Y Net Income Change - - - -22.08 % -13.09 %
Return On Equity -58.93 % -68.76 % -0.2 % 11.12 % 36.5 %

Back to QDEL Management Effectiveness >> QDEL's 5 Years Annual ROE >> Compare QDEL ROE to its Competitors




More Return On Equity Ratios
In Vitro & In Vivo Diagnostic Substances Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
QDEL's' Return on Equity at Yahoo Finance
QDEL's Roe Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for QDEL's Competitors
Subscribers only: Roe for Quidelortho's Suppliers
Subscribers only: Return On Equity for QDEL's Customers




Companies with similar Return On Equity at Jun 28 2026, within Healthcare Sector ROE

Date modified: 2026-09-26T07:41:41+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.